The China Antibody market is valued at 38.68 million USD in 2016 and is expected to reach 81.53 million USD by the end of 2022, growing at a CAGR of 13.23% between 2016 and 2022.
East China plays an important role in China market, with market size of 12.84 million USD in 2016 and will be 29.54 million USD in 2022, with a CAGR of 14.90%.
This report studies the Antibody development status and future trend in China, focuses on top players in China, also splits Antibody by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.
The major players in China market include Hytest Roche Thermo Fisher Fapon Genscript Kitgen Leadman MACCURA Wondfo
Geographically, this report splits the China market into six regions, South China East China Southwest China Northeast China North China Central China
On the basis of product, the Antibody market is primarily split into Polyclonal Antibody Monoclonal Antibody
On the basis on the end users/applications, this report covers Hospital Medical research institutions Others